These values are consistent with plasma versus tissue PPA estimates for FDA‐approved plasma CDx assays, such as Therascreen® PIK3CA RGQ PCR Kit [54.6%; breast cancer (alpelisib)] and cobas® EGFR Mutation Test v2 [≥58.7%; NSCLC (erlotinib, osimertinib, gefitinib)] [29, 30]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.